Sentences with phrase «cancer immunotherapeutics»
Diana joined City of Hope in the department of Cancer Immunotherapeutics and Tumor Immunology in November 2011 where she continues to elucidate mechanisms of immune dysfuction in breast cancer patients as well as aid in identifying antigens recognized by anti-tumor T cells.
https://www.cityofhope.org/
Peter P. Lee, M.D., the Billy and Audrey L. Wilder Professor in Cancer Immunotherapeutics at City of Hope, has for two decades been interested in treating cancer by stimulating or enhancing a person's own immune system.
From home base in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology, Naranjo and Wagner can look across the way to CIty of Hope Helford Clinical Research Hospital, where patients in trials receive infusions of therapeutic CAR T cells.
Recently, he joined Dr. Peter P. Lee's Laboratory in the Department of Cancer Immunotherapeutics and Tumor Immunology (CITI).
«We are moving helter skelter toward a massive application of cancer immunotherapeutics, and we have to understand a lot better what is underpinning the variability of responsiveness so that we can apply those therapies in a rational and grounded way,» Hayday says.
«A lot of studies are underpowered and not controlled appropriately,» says Vincent Brichard, who heads GSK's antigen - specific cancer immunotherapeutics program.
So he joined GSK Vaccines in 2010, as a molecular biologist in the company's Antigen - Specific Cancer Immunotherapeutic program, which aims to harness the immune system for the development of well - tolerated cancer therapies.
Not exact matches
One class of immunotherapeutic drugs is known as «checkpoint» inhibitors, as they target checkpoints in immune system regulation to allow the body's natural defenses, such as white blood cells, to more effectively target the cancer.
«Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted or immunotherapeutic agents as treatment for advanced and very hard - to - treat cancers,» notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park.
Dr. Wolchok is the Lloyd J. Old / Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK); chief of the Melanoma and Immunotherapeutics Service at MSK; and an attending physician at MSK with expertise in the treatment of metastatic melanoma.
These data reinforce the value of the two - dose schedule and should lead to increased utilization of this vaccine, with consequent decreases in morbidity and mortality from cervical cancer,» said Dr. Ronald Ellis, Editor - in - Chief of Human Vaccines & Immunotherapeutics.
One of the immunotherapeutic approaches that has been explored thus far relies on the use of monoclonal antibodies that specifically target a protein present on the surface of prostate cancer cells called prostate specific membrane antigen (PSMA) to elicit an anti-tumor immune response and control the cancer.
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific protein.
«Since the advent of cancer immunotherapy, people have tried to apply immunotherapeutic drugs to mesothelioma with limited success.
Bilthoven, April 21, 2016 - An international multi-disciplinary consortium of 11 partners, in which 5 leading academic institutes, 4 cutting - edge biotech companies and 2 excellent service providers will join forces to advance the treatment of cancer using an innovative immunotherapeutic nanomedicin, has received an $ 8.3 million Horizon 2020 grant (grant agreement No 686089).
In addition to stem cell transplants, which have been used for decades, the immunotherapeutic antibody dinutuximab ⎯ which targets the glycolipid GD2 ⎯ is approved for childhood cancer patients with neuroblastoma.
Dr. Jedd D. Wolchok is the chief of the Melanoma and Immunotherapeutics Service, the Lloyd J. Old / Virginia and Daniel K. Ludwig Chair in Clinical Investigation, and director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.
BiTEs like Blincyto are the latest weapon in the immunotherapeutic arsenal against cancer.
Title: Infiltrating immune cells in breast cancer subtypes Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapecancer subtypes Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeCancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.
Although cancer immunotherapy is changing the paradigm of how cancer is treated, there is an urgent need to develop predictive biomarkers to identify patients who are most likely to benefit from various immunotherapeutic strategies.
Kochi About Blog Manzoor Koyakutty is a Professor at the Amrita Centre for Nanosciences and Molecular Medicine, Cochin, India, specializes in the area of Cancer nanomedicine & immunotherapeutics.
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.
«This immunotherapeutic approach is very promising as it induces a patient's own immune system to combat cancer cells, wherever they may be, from within.»
Kochi About Blog Manzoor Koyakutty is a Professor at the Amrita Centre for Nanosciences and Molecular Medicine, Cochin, India, specializes in the area of Cancer nanomedicine & immunotherapeutics.